Mobile

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-002053-30

A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Determine the recommended phase II dose (RP2D) of MSC2156119J. Evaluate efficacy of MSC2156119J in subjects with MET+ advanced HCC pretreated with sorafenib and Child Pugh class A liver function.

Critère d'inclusion

  • Hepatocellular carcinoma

Liens